Market research
CNTA Centessa Pharmaceuticals PLC ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 40.25
- Dividend yield
- 93.%
- Beta
- 1.12
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1523091007
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 40.25
- Dividend yield
- 93.%
- Beta
- 1.12
About
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CNTA discussion.
No comments yet
Start a focused discussion about CNTA.